Maze Therapeutics (NASDAQ:MAZE) Receives “Buy” Rating from HC Wainwright

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They currently have a $110.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 318.38% from the stock’s previous close.

MAZE has been the topic of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Monday. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. BTIG Research reiterated a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a research note on Tuesday. Wedbush reiterated an “outperform” rating and issued a $48.00 target price on shares of Maze Therapeutics in a research note on Wednesday. Finally, Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Four investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $63.40.

Maze Therapeutics Trading Up 0.3%

MAZE opened at $26.29 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. Maze Therapeutics has a fifty-two week low of $21.95 and a fifty-two week high of $53.65. The firm has a market capitalization of $1.46 billion, a PE ratio of -10.43 and a beta of 2.17. The company’s 50-day moving average is $27.16 and its 200 day moving average is $29.04.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.76). As a group, research analysts predict that Maze Therapeutics will post -2.72 earnings per share for the current fiscal year.

Insider Activity at Maze Therapeutics

In related news, insider Courtney Phillips sold 2,012 shares of Maze Therapeutics stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $52,332.12. Following the completion of the transaction, the insider directly owned 7,007 shares of the company’s stock, valued at $182,252.07. This trade represents a 22.31% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Atul Dandekar sold 3,243 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $84,350.43. Following the sale, the insider directly owned 32,316 shares in the company, valued at $840,539.16. This trade represents a 9.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 191,459 shares of company stock worth $5,263,539. 5.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Maze Therapeutics

Institutional investors have recently made changes to their positions in the company. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Maze Therapeutics during the second quarter valued at approximately $48,000. Royal Bank of Canada increased its holdings in Maze Therapeutics by 214.1% during the first quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock valued at $61,000 after buying an additional 1,383 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Maze Therapeutics during the second quarter valued at approximately $80,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Maze Therapeutics in the fourth quarter worth approximately $145,000. Finally, IFP Advisors Inc bought a new position in shares of Maze Therapeutics in the fourth quarter worth approximately $146,000.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.